Albireo Pharma Stock Price, News & Analysis (NASDAQ:ALBO)

$33.81 -0.14 (-0.41 %)
(As of 02/23/2018 07:30 AM ET)
Previous Close$33.95
Today's Range$33.21 - $35.21
52-Week Range$15.31 - $39.87
Volume23,500 shs
Average Volume93,583 shs
Market Capitalization$368.45 million
P/E RatioN/A
Dividend YieldN/A
Beta1.65

About Albireo Pharma (NASDAQ:ALBO)

Albireo Pharma logoBiodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company's BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.

Receive ALBO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Other
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALBO
CUSIPN/A
Phone857-254-5555

Debt

Debt-to-Equity RatioN/A
Current Ratio7.33%
Quick Ratio7.33%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$11.36 million
Price / Sales32.29
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees12
Outstanding Shares10,850,000

Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) announced its quarterly earnings results on Monday, August, 21st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by $0.02. View Albireo Pharma's Earnings History.

Where is Albireo Pharma's stock going? Where will Albireo Pharma's stock price be in 2018?

4 Wall Street analysts have issued 12-month target prices for Albireo Pharma's stock. Their predictions range from $50.00 to $92.00. On average, they expect Albireo Pharma's stock price to reach $66.67 in the next year. View Analyst Ratings for Albireo Pharma.

What are Wall Street analysts saying about Albireo Pharma stock?

Here are some recent quotes from research analysts about Albireo Pharma stock:

  • 1. According to Zacks Investment Research, "Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. " (1/24/2018)
  • 2. Wedbush analysts commented, "Zynerba updated its plans to focus development on rare and near-rare neurological and psychiatric disorders." (1/3/2018)
  • 3. Cowen Inc analysts commented, "Albireo reported 3Q earnings today and provided a brief summary of recent progress." (11/17/2017)
  • 4. Needham & Company LLC analysts commented, "Albireo hosted a KOL meeting yesterday in NYC to discuss Progressive Familial Intrahepatic Cholestasis (PFIC) and provide an update on A4250 clinical program. E. Sturm, investigator in A4250 Phase 2 trial in pediatric cholestasis, highlighted unmet need in PFIC and other rare pediatric cholestasis indications. Biliary diversion surgery is effective option for reducing bile acids in serum, but has 20-40% failure rate. Dr. Sturm is eager for other options and views AB4250 Phase 2 safety and efficacy profile as compelling. Initiation of Phase 3 trial in PFIC1 and PFIC2 patients expected around YE17." (10/26/2017)

Who are some of Albireo Pharma's key competitors?

Who owns Albireo Pharma stock?

Albireo Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (12.17%), Artal Group S.A. (2.76%), Sectoral Asset Management Inc (2.24%), Renaissance Technologies LLC (1.11%), Millennium Management LLC (0.43%) and Sphera Funds Management LTD. (0.33%). Company insiders that own Albireo Pharma stock include Life Sciences Maste Perceptive, Phase4 Partners Ltd and Plc Astrazeneca. View Institutional Ownership Trends for Albireo Pharma.

Who sold Albireo Pharma stock? Who is selling Albireo Pharma stock?

Albireo Pharma's stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Renaissance Technologies LLC and Hartwell J M Limited Partnership. Company insiders that have sold Albireo Pharma company stock in the last year include Phase4 Partners Ltd and Plc Astrazeneca. View Insider Buying and Selling for Albireo Pharma.

Who bought Albireo Pharma stock? Who is buying Albireo Pharma stock?

Albireo Pharma's stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Artal Group S.A., Sectoral Asset Management Inc, Millennium Management LLC, Ardsley Advisory Partners, Bank of New York Mellon Corp and Wells Fargo & Company MN. View Insider Buying and Selling for Albireo Pharma.

How do I buy Albireo Pharma stock?

Shares of Albireo Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Albireo Pharma's stock price today?

One share of Albireo Pharma stock can currently be purchased for approximately $33.81.

How big of a company is Albireo Pharma?

Albireo Pharma has a market capitalization of $368.45 million and generates $11.36 million in revenue each year. Albireo Pharma employs 12 workers across the globe.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]


MarketBeat Community Rating for Albireo Pharma (ALBO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  106 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Albireo Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Albireo Pharma (NASDAQ:ALBO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $66.67$61.67$61.67$35.00
Price Target Upside: 94.36% upside86.87% upside137.27% upside63.32% upside

Albireo Pharma (NASDAQ:ALBO) Consensus Price Target History

Price Target History for Albireo Pharma (NASDAQ:ALBO)

Albireo Pharma (NASDAQ:ALBO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/2/2018Needham & Company LLCBoost Price TargetBuy$50.00LowView Rating Details
1/19/2018WedbushReiterated RatingBuyLowView Rating Details
11/17/2017CowenReiterated RatingBuyN/AView Rating Details
11/15/2017Roth CapitalInitiated CoverageBuy -> Buy$92.00N/AView Rating Details
2/16/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuyN/AView Rating Details
1/25/2017William BlairInitiated CoverageOutperformN/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Albireo Pharma (NASDAQ:ALBO) Earnings History and Estimates Chart

Earnings by Quarter for Albireo Pharma (NASDAQ:ALBO)

Albireo Pharma (NASDAQ ALBO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.85)($0.73)ViewN/AView Earnings Details
8/21/20176/30/2017($0.84)($0.86)ViewN/AView Earnings Details
5/10/2017Q2 2017($1.11)($1.06)ViewN/AView Earnings Details
8/11/2016Q216($0.05)ViewN/AView Earnings Details
5/9/2016Q2($0.04)($0.09)ViewN/AView Earnings Details
2/16/2016Q1($0.08)($0.05)ViewN/AView Earnings Details
12/17/2015Q315($0.11)($0.05)ViewListenView Earnings Details
8/13/2015Q3($0.10)($0.12)ViewListenView Earnings Details
5/6/2015Q215($0.23)($0.27)ViewN/AView Earnings Details
2/12/2015Q115($0.18)($0.20)ViewN/AView Earnings Details
12/17/2014Q414($0.27)($0.16)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.26)($0.15)ViewN/AView Earnings Details
5/13/2014Q114($0.26)($0.29)ViewN/AView Earnings Details
2/6/2014Q4($0.19)($0.20)ViewN/AView Earnings Details
12/18/2013Q4($0.30)($0.04)ViewListenView Earnings Details
8/12/2013Q3 2013($0.37)($0.66)ViewN/AView Earnings Details
5/8/2013Q2 2013($0.43)($0.37)ViewN/AView Earnings Details
2/12/2013Q4 2012($12.91)($12.61)ViewN/AView Earnings Details
12/18/2012Q3 2012($13.81)($12.31)ViewN/AView Earnings Details
8/8/2012Q2 2012($16.22)($13.39)ViewN/AView Earnings Details
5/10/2012Q1 2012($18.02)($13.33)ViewN/AView Earnings Details
2/8/2012Q4 2011($16.82)($13.93)ViewN/AView Earnings Details
12/6/2011Q3 2011($20.42)($15.86)ViewN/AView Earnings Details
8/4/2011Q2 2011($25.23)($17.66)ViewN/AView Earnings Details
5/5/2011Q1 2011($31.23)($24.74)ViewN/AView Earnings Details
2/3/2011Q4 2010($33.63)($24.14)ViewN/AView Earnings Details
12/9/2010Q3 2010($44.44)($37.24)ViewN/AView Earnings Details
8/5/2010Q2 2010($48.05)($43.24)ViewN/AView Earnings Details
5/6/2010Q1 2010($50.45)($52.37)ViewN/AView Earnings Details
2/4/2010Q4 2009($51.65)($56.10)ViewN/AView Earnings Details
12/14/2009Q3 2009($60.06)($52.97)ViewN/AView Earnings Details
8/7/2009Q2 2009($61.26)($56.34)ViewN/AView Earnings Details
5/7/2009Q1 2009($50.45)($58.86)ViewN/AView Earnings Details
2/5/2009Q4 2008($50.45)($50.81)ViewN/AView Earnings Details
12/10/2008Q3 2008($54.05)($63.66)ViewN/AView Earnings Details
8/6/2008Q2 2008($54.05)($51.29)ViewN/AView Earnings Details
5/9/2008Q1 2008($56.46)($52.13)ViewN/AView Earnings Details
2/14/2008Q4 2007($54.05)($65.59)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Albireo Pharma (NASDAQ:ALBO) Earnings Estimates

2018 EPS Consensus Estimate: ($3.36)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.92)($0.76)($0.84)
Q2 20182($0.98)($0.75)($0.87)
Q3 20182($1.05)($0.56)($0.81)
Q4 20182($1.13)($0.57)($0.85)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Albireo Pharma (NASDAQ:ALBO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Albireo Pharma (NASDAQ ALBO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 22.30%
Institutional Ownership Percentage: 26.78%
Insider Trades by Quarter for Albireo Pharma (NASDAQ:ALBO)
Institutional Ownership by Quarter for Albireo Pharma (NASDAQ:ALBO)

Albireo Pharma (NASDAQ ALBO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/30/2018Phase4 Partners LtdMajor ShareholderSell100,000$34.44$3,444,000.00View SEC Filing  
1/25/2018Life Sciences Maste PerceptiveMajor ShareholderBuy275,000$33.00$9,075,000.00View SEC Filing  
12/1/2017Plc AstrazenecaMajor ShareholderSell500,000$21.40$10,700,000.00View SEC Filing  
12/20/2013Brian Jg PereiraDirectorSell4,734$2.26$10,698.84View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Albireo Pharma (NASDAQ ALBO) News Headlines

Source:
DateHeadline
Albireo Pharma (ALBO) and Alexza Pharmaceuticals (ALXA) Critical ReviewAlbireo Pharma (ALBO) and Alexza Pharmaceuticals (ALXA) Critical Review
www.americanbankingnews.com - February 20 at 9:08 PM
Head-To-Head Contrast: Albireo Pharma (ALBO) versus Alexza Pharmaceuticals (ALXA)Head-To-Head Contrast: Albireo Pharma (ALBO) versus Alexza Pharmaceuticals (ALXA)
www.americanbankingnews.com - February 17 at 7:32 PM
Analyzing Alexza Pharmaceuticals (ALXA) and Albireo Pharma (ALBO)Analyzing Alexza Pharmaceuticals (ALXA) and Albireo Pharma (ALBO)
www.americanbankingnews.com - February 17 at 1:16 AM
Reviewing Albireo Pharma (ALBO) and Alexza Pharmaceuticals (ALXA)Reviewing Albireo Pharma (ALBO) and Alexza Pharmaceuticals (ALXA)
www.americanbankingnews.com - February 15 at 11:12 PM
Critical Comparison: Alexza Pharmaceuticals (ALXA) and Albireo Pharma (ALBO)Critical Comparison: Alexza Pharmaceuticals (ALXA) and Albireo Pharma (ALBO)
www.americanbankingnews.com - February 8 at 11:20 AM
Albireo Pharma, Inc. (ALBO) Receives Consensus Recommendation of "Buy" from AnalystsAlbireo Pharma, Inc. (ALBO) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 7 at 3:24 AM
Needham & Company LLC Raises Albireo Pharma (ALBO) Price Target to $50.00Needham & Company LLC Raises Albireo Pharma (ALBO) Price Target to $50.00
www.americanbankingnews.com - February 2 at 2:25 PM
Albireo Pharma, Inc. (ALBO) Major Shareholder Sells $3,444,000.00 in StockAlbireo Pharma, Inc. (ALBO) Major Shareholder Sells $3,444,000.00 in Stock
www.americanbankingnews.com - February 1 at 6:10 PM
Albireo Announces Closing of $74.8 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional SharesAlbireo Announces Closing of $74.8 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - January 29 at 4:28 PM
Albireo Pharma, Inc. (ALBO) Major Shareholder Life Sciences Maste Perceptive Buys 275,000 SharesAlbireo Pharma, Inc. (ALBO) Major Shareholder Life Sciences Maste Perceptive Buys 275,000 Shares
www.americanbankingnews.com - January 25 at 9:12 PM
Albireo Prices $65.0 Million Public Offering of Common StockAlbireo Prices $65.0 Million Public Offering of Common Stock
finance.yahoo.com - January 25 at 9:05 AM
Zacks: Analysts Anticipate Albireo Pharma, Inc. (ALBO) to Post -$0.78 EPSZacks: Analysts Anticipate Albireo Pharma, Inc. (ALBO) to Post -$0.78 EPS
www.americanbankingnews.com - January 24 at 11:10 PM
Albireo Announces Proposed Public Offering of Common StockAlbireo Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 24 at 4:47 PM
Albireo Pharma (ALBO) Stock Rating Lowered by Zacks Investment ResearchAlbireo Pharma (ALBO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 24 at 4:06 PM
Albireo Pharmas (ALBO) Buy Rating Reaffirmed at WedbushAlbireo Pharma's (ALBO) Buy Rating Reaffirmed at Wedbush
www.americanbankingnews.com - January 19 at 8:44 PM
Albireo to Receive More than $55 Million(1) in Nondilutive Cash PaymentsAlbireo to Receive More than $55 Million(1) in Nondilutive Cash Payments
finance.yahoo.com - January 19 at 12:19 PM
Albireo Pharma (ALBO) Downgraded to Hold at Zacks Investment ResearchAlbireo Pharma (ALBO) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - January 17 at 4:42 PM
Albireo Pharma (ALBO) Rating Increased to Buy at Zacks Investment ResearchAlbireo Pharma (ALBO) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 16 at 4:36 PM
Albireo Pharma, Inc. (ALBO) Given Consensus Recommendation of "Buy" by AnalystsAlbireo Pharma, Inc. (ALBO) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 13 at 4:01 AM
Albireo Pharma (ALBO) Downgraded by Zacks Investment ResearchAlbireo Pharma (ALBO) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 11 at 4:52 PM
Albireo Pharma (ALBO) Stock Rating Upgraded by Zacks Investment ResearchAlbireo Pharma (ALBO) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 8 at 9:26 PM
Wedbush Equities Analysts Increase Earnings Estimates for Albireo Pharma, Inc. (ALBO)Wedbush Equities Analysts Increase Earnings Estimates for Albireo Pharma, Inc. (ALBO)
www.americanbankingnews.com - January 8 at 7:12 AM
William Blair Comments on Albireo Pharma, Inc.s Q1 2018 Earnings (ALBO)William Blair Comments on Albireo Pharma, Inc.'s Q1 2018 Earnings (ALBO)
www.americanbankingnews.com - January 8 at 6:02 AM
Zacks: Brokerages Expect Albireo Pharma, Inc. (ALBO) Will Post Earnings of -$0.78 Per ShareZacks: Brokerages Expect Albireo Pharma, Inc. (ALBO) Will Post Earnings of -$0.78 Per Share
www.americanbankingnews.com - January 7 at 7:24 PM
Albireo Pharma, Inc. (ALBO) to Post FY2022 Earnings of $7.44 Per Share, Wedbush ForecastsAlbireo Pharma, Inc. (ALBO) to Post FY2022 Earnings of $7.44 Per Share, Wedbush Forecasts
www.americanbankingnews.com - January 5 at 8:24 PM
Wedbush Reaffirms Buy Rating for Albireo Pharma (ALBO)Wedbush Reaffirms Buy Rating for Albireo Pharma (ALBO)
www.americanbankingnews.com - January 3 at 9:22 PM
Albireo Announces Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat in JapanAlbireo Announces Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat in Japan
finance.yahoo.com - January 3 at 9:55 AM
Albireo Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Albireo Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - December 29 at 4:11 PM
Albireo Pharma, Inc. (ALBO) Expected to Announce Earnings of -$0.78 Per ShareAlbireo Pharma, Inc. (ALBO) Expected to Announce Earnings of -$0.78 Per Share
www.americanbankingnews.com - December 22 at 1:22 PM
Biodel Inc. (ALBO) Given Average Rating of "Buy" by BrokeragesBiodel Inc. (ALBO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 19 at 3:36 AM
Biodel Inc. to Post FY2017 Earnings of ($3.33) Per Share, Wedbush Forecasts (ALBO)Biodel Inc. to Post FY2017 Earnings of ($3.33) Per Share, Wedbush Forecasts (ALBO)
www.americanbankingnews.com - December 11 at 2:10 AM
Critical Analysis: RegeneRx Biopharmaceuticals (RGRX) and Biodel (ALBO)Critical Analysis: RegeneRx Biopharmaceuticals (RGRX) and Biodel (ALBO)
www.americanbankingnews.com - December 7 at 3:32 AM
Biodel Inc. (ALBO) Major Shareholder Sells $10,700,000.00 in StockBiodel Inc. (ALBO) Major Shareholder Sells $10,700,000.00 in Stock
www.americanbankingnews.com - December 5 at 5:36 PM
 Analysts Anticipate Biodel Inc. (ALBO) to Announce -$0.78 EPS Analysts Anticipate Biodel Inc. (ALBO) to Announce -$0.78 EPS
www.americanbankingnews.com - December 4 at 3:14 PM
RegeneRx Biopharmaceuticals (RGRX) & Biodel (ALBO) Critical ComparisonRegeneRx Biopharmaceuticals (RGRX) & Biodel (ALBO) Critical Comparison
www.americanbankingnews.com - December 4 at 1:28 PM
Analyzing RegeneRx Biopharmaceuticals (RGRX) and Biodel (ALBO)Analyzing RegeneRx Biopharmaceuticals (RGRX) and Biodel (ALBO)
www.americanbankingnews.com - December 1 at 5:40 AM
Financial Comparison: Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX)Financial Comparison: Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - November 27 at 12:15 PM
Comparing Biodel (ALBO) & RegeneRx Biopharmaceuticals (RGRX)Comparing Biodel (ALBO) & RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - November 26 at 5:10 AM
Analyzing Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX)Analyzing Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - November 25 at 1:16 PM
Biodel Inc. (ALBO) Receives Consensus Rating of "Buy" from BrokeragesBiodel Inc. (ALBO) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 24 at 3:56 AM
Critical Contrast: RegeneRx Biopharmaceuticals (RGRX) & Biodel (ALBO)Critical Contrast: RegeneRx Biopharmaceuticals (RGRX) & Biodel (ALBO)
www.americanbankingnews.com - November 19 at 9:28 AM
Biodel Inc. Expected to Earn FY2017 Earnings of ($3.40) Per Share (ALBO)Biodel Inc. Expected to Earn FY2017 Earnings of ($3.40) Per Share (ALBO)
www.americanbankingnews.com - November 17 at 9:44 PM
Biodel Inc. (ALBO) Stock Rating Reaffirmed by Cowen and CompanyBiodel Inc. (ALBO) Stock Rating Reaffirmed by Cowen and Company
www.americanbankingnews.com - November 17 at 7:58 PM
Zacks: Analysts Anticipate Biodel Inc. (ALBO) to Announce -$0.82 Earnings Per ShareZacks: Analysts Anticipate Biodel Inc. (ALBO) to Announce -$0.82 Earnings Per Share
www.americanbankingnews.com - November 16 at 5:18 AM
Biodel Inc. (ALBO) Coverage Initiated by Analysts at Roth CapitalBiodel Inc. (ALBO) Coverage Initiated by Analysts at Roth Capital
www.americanbankingnews.com - November 15 at 11:41 AM
Albireo Reports Third Quarter 2017 Financial ResultsAlbireo Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 4:13 PM
Zacks Investment Research Lowers Biodel Inc. (ALBO) to HoldZacks Investment Research Lowers Biodel Inc. (ALBO) to Hold
www.americanbankingnews.com - November 13 at 8:30 PM
Albireo to Present at the Jefferies 2017 London Healthcare ConferenceAlbireo to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 9 at 4:44 PM
Biodel Inc. (ALBO) Receives Average Rating of "Buy" from BrokeragesBiodel Inc. (ALBO) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 30 at 1:40 AM
Biodel Inc. (ALBO) Receives "Buy" Rating from Needham & Company LLCBiodel Inc. (ALBO) Receives "Buy" Rating from Needham & Company LLC
www.americanbankingnews.com - October 26 at 11:58 PM

SEC Filings

Albireo Pharma (NASDAQ:ALBO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Albireo Pharma (NASDAQ:ALBO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Albireo Pharma (NASDAQ ALBO) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.